Table 5 Results of the revised market mix (“To be” scenario)
Revised market mix | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
Population | 203 018 | 203 018 | 203 018 |
Direct healthcare costs | |||
QIVe acquisition costs | €1 063 814.84 | €930 837.99 | €797 861.13 |
QIVc acquisition costs | €304 527.15 | €456 790.73 | €609 054.30 |
Vaccine administration costs | €1 250 591.50 | €1 250 591.50 | €1 250 591.50 |
Total acquisition and administration costs | €2 618 933.49 | €2 638 220.21 | €2 657 506.93 |
Influenza cases among vaccinated HCWs | |||
Vaccination with QIVe | 3865 | 3382 | 2899 |
Vaccination with QIVc | 770 | 1155 | 1540 |
Influenza cases with symptoms among vaccinated HCWs | |||
HCWs with influenza and symptoms | 3101 | 3035 | 2969 |
Costs of prescribed influenza drugs | €43 107.76 | €42 194.07 | €41 280.38 |
Costs of influenza drugs without prescription | €23 524.64 | €23 026.02 | €22 527.41 |
Influenza-related GP visitsa | €15 253.46 | €14 930.15 | €14 606.85 |
Total direct healthcare costs | €2 700 819.35 | €2 718 370.46 | €2 735 921.57 |
Fiscal impact | |||
QIVe | €110 393.88 | €96 594.65 | €82 795.41 |
QIVc | €21 986.73 | €32 980.09 | €43 973.46 |
Total fiscal impact | €132 380.61 | €129 574.74 | €126 768.87 |
Indirect costs (productivity losses) | |||
QIVe | €1 510 176.26 | €1 321 404.23 | €1 132 632.19 |
QIVc | €300 776.03 | €451 164.04 | €601 552.05 |
Total indirect costs | €1 810 952.29 | €1 772 568.27 | €1 734 184.25 |
Total (direct costs + indirect costs + fiscal impact) | €4 644 152.25 | €4 620 513.47 | €4 596 874.69 |